Table 1.
Survival of high-risk genetic subgroups on randomized controlled clinical trials of thalidomide and bortezomib in untreated MM
| Genetics | N1/N2 | Endpoint | Arm 1 | Arm 2 | Arm 1 (%) | Arm 2 (%) | Comment |
|---|---|---|---|---|---|---|---|
| t(4;14) | 26/24 | 3-year OS | V-AD/ASCT/Thal | Bz-AD/ASCT/Bz | 44 | 66 | HOVON/GMMG [77] |
| 98/106 | 4-year OS | VA-D | Bz-D | 32 | 63 | IFM-2005 [68] | |
| 21/23 | 2-year OS | Thal | Placebo | 67 | 87 | TT2 [72] | |
| 21/29 | 2-year OS | Thal-TT2 | Bz-TT3 | 67 | 97 | TT2 v. TT3 [71] | |
| del17p | 21/16 | 3-year OS | V-AD/ASCT/Thal | Bz-AD/ASCT/Bz | 17 | 69 | HOVON/GMMG [77] |
| 119/54 | 4-year OS | VA-D | Bz-D | 36 | 50 | IFM-2005 [68] | |
| Non-hyperdiploid | 92 | 3-year OS | Thal-D-Bz | Mel-P-Bz | 53 | 72 | PETHEMA [76] |
| Unfav. FISH | 152/141 | 3-year OS | Thal-D-Cyclo | VA-D-Cyclo | 58 | 56 | MRC-IX intensive [86] |
| 96/90 | 3-year OS | Thal-D-Cyclo | Placebo-P-Mel | 34 | 26 | MRC-IX non-intens [75] | |
| 99/98 | 3-year OS | Thal maint | Placebo maint | 45 | 69 | MRC-IX maint [73] |
The drugs randomized in Arm 1 vs Arm 2 are highlighted in bold, as are the survival outcomes that are significantly superior
V vincristine, A adriamycin, D dexamethasone, ASCT autologous stem cell transplant, Thal thalidomide, Bz bortezomib, TT2 total therapy 2, TT3 total therapy 3, Mel low dose oral melphalan, P prednisone, Cyclo cyclophosphamide, / implies sequential therapies